logo
Plus   Neg
Share
Email

ObsEva Submits MAA To EMA For YSELTY For Treatment Of Women With Uterine Fibroids

ObsEva SA (OBSV) said that it has submitted a marketing authorization application to the European Medicines Agency or EMA for YSELTY or linzagolix 100mg and linzagolix 200mg for the management of heavy menstrual bleeding associated with uterine fibroids.

ObsEva expects that the EMA will notify the company in December 2020 regarding the outcome of its validation of the MAA to ensure all essential regulatory elements required for a scientific assessment are included in the application prior to the start of the procedure.

ObsEva expects to submit a new drug application to U.S. Food and Drug Administration in the first-half of 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year.
RELATED NEWS
Follow RTT